{'fraction_non_alphanumeric': 0.028720626631853787, 'fraction_numerical': 0.028720626631853787, 'mean_word_length': 4.9921875, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
OK-432 therapy for lymphangiomas.

OBJECTIVE
To assess the efficacy of OK-432 sclerotherapy in the treatment of lymphangiomas.


DESIGN
Nonrandomized trial; follow-up, 4 to 29 months.


SETTING
Academic tertiary referral medical center.


PATIENTS
Six children with presumed lymphangiomas; age range at initial treatment, 1 month to 7 years 10 months.


INTERVENTION
Fluoroscopically guided cyst aspiration, cystography, and injection of OK-432.


OUTCOME MEASURES
Clinical and radiographic comparisons before and after therapy.


RESULTS
Complete response in 2 macrocystic lymphangiomas; no response in 3 microcystic lymphangiomas; and no response in 1 venous malformation.


CONCLUSION
OK-432 sclerotherapy may be effective treatment for macrocystic lymphangiomas.